Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Elucidating the biological role of LonP1 in Acute Myeloid Leukemia and its potential as a therapeutic target for this disease
EF 2022-23
Résumé
My proposed research involves investigating a mitochondria protease, LonP1, in acute myeloid leukemia (AML). Proteases including LonP1 are responsible for protein quality control and their job is to break down damaged and aggregated proteins in a cell. Our primary data shows a dependency on LonP1 in a subset of AML cell lines. After genetically modifying AML cells to be incapable of synthesizing LonP1, we observed a reduction in AML cell growth. We found overexpression of LonP1 protein in subset of cell lines and primary patient samples compared to normal hematopoietic cells. My goal is to investigate the biological role of LonP1 in AML and potentially discover a novel therapeutic target AML.
Specifically, I plan to investigate the correlation between basal-level LonP1 expression and protein aggregation. Our initial results show that LonP1 protein is overexpressed in cell lines compared to normal hematopoietic cells. We aim to identify a subset of AML patients that are more sensitive to LonP1 therapy which we hypothesize are those with high basal level LonP1 expression and protein aggregation. I will expand this analysis to primary patient samples and better understand the heterogeneity and relationship between LonP1 and protein aggregation. Next, I will investigate the specific functional domains of LonP1. LonP1 has two domains, ATPase and proteolytic, and we hypothesize that the ATPase domain is essential in this context. I will genetically manipulate cell produce only LonP1 with non-functional ATPase or proteolytic domain and evaluate its effect on protein aggregation, growth, and viability. Lastly, I will test other existing pharmacological inhibitors that can synergize with LonP1 inhibition. This will be discovering potential combinational therapy strategies.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
485886
Name
Zhang Lan Xin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidating the biological role of LonP1 in Acute Myeloid Leukemia and its potential as a therapeutic target for this disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Leukemia; Mechanism; Mitochondria; Protease; Therapy
Abstract
My proposed research involves investigating a mitochondria protease, LonP1, in acute myeloid leukemia (AML). Proteases including LonP1 are responsible for protein quality control and their job is to break down damaged and aggregated proteins in a cell. Our primary data shows a dependency on LonP1 in a subset of AML cell lines. After genetically modifying AML cells to be incapable of synthesizing LonP1, we observed a reduction in AML cell growth. We found overexpression of LonP1 protein in subset of cell lines and primary patient samples compared to normal hematopoietic cells. My goal is to investigate the biological role of LonP1 in AML and potentially discover a novel therapeutic target AML.
Specifically, I plan to investigate the correlation between basal-level LonP1 expression and protein aggregation. Our initial results show that LonP1 protein is overexpressed in cell lines compared to normal hematopoietic cells. We aim to identify a subset of AML patients that are more sensitive to LonP1 therapy which we hypothesize are those with high basal level LonP1 expression and protein aggregation. I will expand this analysis to primary patient samples and better understand the heterogeneity and relationship between LonP1 and protein aggregation. Next, I will investigate the specific functional domains of LonP1. LonP1 has two domains, ATPase and proteolytic, and we hypothesize that the ATPase domain is essential in this context. I will genetically manipulate cell produce only LonP1 with non-functional ATPase or proteolytic domain and evaluate its effect on protein aggregation, growth, and viability. Lastly, I will test other existing pharmacological inhibitors that can synergize with LonP1 inhibition. This will be discovering potential combinational therapy strategies.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zhang, Lan Xin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~